Ardelyx (ARDX) Research & Development (2013 - 2026)
Ardelyx's (ARDX) quarterly Research & Development came in at $20.2 million in Q1 2026, up 35.15% YoY from $14.9 million in Q1 2025, and down 11.67% on a QoQ basis from $22.9 million in Q4 2025.
Ardelyx (ARDX) Research & Development (2013 - 2026) Analysis & Trends
Ardelyx (ARDX) has 14 years of Research & Development data on file, last reported at $20.2 million in Q1 2026.
- Quarterly Research & Development rose 35.15% year-over-year to $20.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $76.8 million (up 35.47% YoY) and the FY2025 annual result came in at $71.5 million, up 36.72% from the prior year.
- Research & Development fell to $20.2 million in Q1 2026, from $22.9 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $22.9 million in Q4 2025 to a low of $7.5 million in Q3 2022.
- A 5-year average of $12.6 million and a median of $10.6 million in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development plunged 68.49% — and 2024, when it surged 77.26%.
- Tracing ARDX's Research & Development over 5 years: stood at $9.1 million in 2022, then rose by 4.18% to $9.5 million in 2023, then soared by 43.49% to $13.7 million in 2024, then jumped by 67.25% to $22.9 million in 2025, then declined by 11.67% to $20.2 million in 2026.
- The last three Research & Development figures came in at $20.2 million (Q1 2026), $22.9 million (Q4 2025), and $18.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Ardelyx | 1.01 Bn | 729.71 Mn | 115.12 Mn | 26.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.10 Mn |
| Mar 31, 2026 | 20.19 Mn |
| Dec 31, 2025 | 22.86 Mn |
| Sep 30, 2025 | 18.07 Mn |
| Jun 30, 2025 | 15.67 Mn |
| Mar 31, 2025 | 14.94 Mn |
| Dec 31, 2024 | 13.67 Mn |
| Sep 30, 2024 | 15.31 Mn |
| Jun 30, 2024 | 12.76 Mn |
| Mar 31, 2024 | 10.58 Mn |
| Dec 31, 2023 | 9.52 Mn |
| Sep 30, 2023 | 8.64 Mn |
| Jun 30, 2023 | 8.28 Mn |
| Mar 31, 2023 | 9.09 Mn |
| Dec 31, 2022 | 9.14 Mn |
| Sep 30, 2022 | 7.47 Mn |
| Jun 30, 2022 | 9.74 Mn |
| Mar 31, 2022 | 8.85 Mn |
| Dec 31, 2021 | 20.97 Mn |
| Sep 30, 2021 | 23.70 Mn |